By a News Reporter-Staff News Editor at Biotech Week -- Fresh data on Biotechnology are presented in a new report. According to news reporting originating in Hangzhou, People's Republic of China, by NewsRx journalists, research stated, "Therapeutic strategies based on modulation of microRNA activity possess much promise in cancer therapy, but the in vivo delivery of microRNA to target sites and its penetration into tumor tissues remain great challenge. In this work, miR-34a-delivering therapeutic nanocomplexes with a tumor-targeting and -penetrating bifunctional CC9 peptide were proposed for efficient treatment of pancreatic cancers."
The news reporters obtained a quote from the research from Zhejiang University, "In vitro study indicated that the nanoparticle-based miR-34a delivery systems could effectively facilitate cellular uptake and greatly up-regulate the mRNA level of miR-34a in PANC-1 cell lines. The up-regulation of miR-34a remarkably induced cell cycle arrest and apoptosis, suppressed the tumor cell migration and inhibited the target gene expressions such as E2F3, Bcl-2, c-myc and cyclin D1. More importantly, the in vivo systemic administration of the developed targeting miR-34a delivery systems in a pancreatic cancer model significantly inhibited tumor growth and induced cancer cell apoptosis."
According to the news reporters, the research concluded: "Such bifunctional peptide-conjugated miRNA-delivering nanocomplexes should have great potential applications in cancer therapy."
For more information on this research see: Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC-1 xenograft model. Biomaterials, 2013;34(9):2265-76. (Elsevier - www.elsevier.com; Biomaterials - www.elsevier.com/wps/product/cws_home/30392)
Our news correspondents report that additional information may be obtained by contacting Q.L. Hu, Institute of Chemical Biology and Pharmaceutical Chemistry, Zhejiang University, Hangzhou, 310028, People's Taiwan. Additional authors for this research include Q.Y. Jiang, X. Jin, J. Shen, K. Wang, Y.B. Li, F.J. Xu, G.P. Tang and Z.H Li (see also technology.html">Biotechnology).
Keywords for this news article include: Asia, Biotechnology, Cancer, Therapy, Hangzhou, Oncology, Peptides, Proteins, Treatment, Xenograft, Amino Acids, Xenotransplantion, People's Republic of China.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC